The Medicines and Healthcare products Regulatory Agency, or MHRA, of the United Kingdom has approved the medicine ganaxolone, or Ztalmy, as “the first anti-seizure medication in the UK to treat cyclin-dependent kinase-like 5 deficiency disorder,” or CDD, the regulator announced. The new marketing authorisation was granted on March 7 to Marinus Pharmaceuticals Emerald Limited.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNS:
